Payout ratios above 75% are not desirable because they may not be sustainable. Announces Effectiveness of Four-to-One Reverse Stock Split, FS KKR Capital Corp. Stable operating expenses support Ares Capital's (ARCC) Q2 results. FS KKR Capital Corp. Its objectives are to generate current income and, to a lesser extent, long-term capital appreciation. It pays a dividend yield of 15.37%, putting its dividend yield in the top 25% of dividend-paying stocks. Given the strong performance of one of its products and its $1.52 share price, some members of the Street think that now is the time to snap up shares.Singing the healthcare name’s praises is Cantor analyst Louise Chen. One share of FSKR stock can currently be purchased for approximately $14.29. Vote “Outperform” if you believe FSKR will outperform the S&P 500 over the long term. View FS KKR Capital Corp. II's dividend history. Cookie Notice. When autocomplete results are available use up and down arrows to review and enter to select. View the latest FS KKR Capital Corp. (FSK) stock price, news, historical charts, analyst ratings and financial information from WSJ. This month, another burst of volatility was brought on by concerns about the U.S. economic recovery, hefty valuations, and a second wave of COVID-19. KKR Capital Markets (KCM) supports our firm, portfolio companies, and clients by providing tailored capital markets advice and developing and implementing both traditional and nontraditional capital solutions for investments and companies seeking financing. Analysts Aren't Bullish on Factset Research Systems Stock…Is it a Contrarian Buy? Do the numbers hold clues to what lies ahead for the stock? © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. FS KKR Capital Corp II (NYSE:FSKR) Q2 2020 Earnings Conference Call August 11, 2020, 11:00 ET Company Participants Robert Paun - Head, IR Michael Forman - CEO Daniel Pietrzak - … The Company manages investments such as private equity, energy, infrastructure, real estate, credit strategies, and hedge funds.

Buprenorphine, the active ingredient, is a partial opioid agonist and is classified as a Schedule III controlled substance, with other opioids like fentanyl, morphine and oxycodone being deemed Schedule II. IPL 2020 Orange Cap Holder: Faf du Plessis Remains Highest Run-getter So Far After MI vs KKR Match. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View our full suite of financial calendars and market data tables, all for free.
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FS KKR Capital Corp. II in the last year. By clicking “OK” below, I acknowledge that I have read and understood the following important information: Access to the KKR Investor Portal is provided to investors in Drawbridge Realty Partners, L.P. (the “Drawbridge Fund”) by Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”) solely in KKR’s capacity as an administrator to the Drawbridge Fund and at the direction of Drawbridge Realty (“Drawbridge”). Like VYNE’s therapy, COVID-19 impacted the launch, but Rx trends are also rebounding, with the company expecting peak sales to reach $150-$200 million.

Get short term trading ideas from the MarketBeat Idea Engine. FS KKR Capital Corp. Dividend policy Increase Price as of: SEP 23, 02:40 PM EDT $15.48 -0.22 -1.4% Watchlist Overview. With an average price target of $7.75, the upside potential comes in at 413%. No person should rely upon the past performance or reputation of KKR or its investment products when considering any security offered by the Drawbridge Fund or Drawbridge. If KKR players are being mentioned in the Orange Cap discussion, Russell might just force his way into it.


Before it's here, it's on the Bloomberg Terminal. FS KKR Capital Corp. II has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating. Looking for new stock ideas? Seysara is an oral product developed by Almirall for the same indication. A Time Warner Company.